Short-course BDQ-containing regimens. BDQ, bedaquiline; PO, oral... | Download Scientific Diagram
Keeping up with the guidelines: design changes to the STREAM stage 2 randomised controlled non-inferiority trial for rifampicin-resistant tuberculosis | Trials | Full Text
Predicting the Outcomes of New Short-Course Regimens for Multidrug-Resistant Tuberculosis Using Intrahost and Pharmacokinetic-Pharmacodynamic Modeling | Antimicrobial Agents and Chemotherapy
Frontiers | Comparative effectiveness of individualized longer and standardized shorter regimens in the treatment of multidrug resistant tuberculosis in a high burden country
Annex. Summary of changes in policy on DS-TB treatment since 2010 and mapping of recommendations in consolidated DS-TB guidelines | TB Knowledge Sharing
Multi‐drug resistant and rifampin‐resistant tuberculosis in transplant recipients - Abad - 2023 - Transplant Infectious Disease - Wiley Online Library
2.4 Drug-resistant TB treatment
Drugs and doses used in shorter MDR regimen for patients older than 14... | Download Scientific Diagram
The global impact of household contact management for children on multidrug-resistant and rifampicin-resistant tuberculosis cases, deaths, and health-system costs in 2019: a modelling study - The Lancet Global Health
India: share of TB patients on treatment versus short MDR TB treatment regimen 2020 | Statista
New drugs and perspectives for new anti-tuberculosis regimens - ScienceDirect
Tuberculosis management - Wikipedia
Timeline of changes to trial design and release of WHO treatment guidelines | Download Scientific Diagram
All-oral longer regimens are effective for the management of multidrug-resistant tuberculosis in high-burden settings | European Respiratory Society
4.3 Algorithm 3 – DST for second-line drugs for RR-TB or MDR-TB patients | TB Knowledge Sharing
Selecting an appropriate all-oral short-course regimen for patients with multidrug-resistant or pre-extensive drug-resistant tuberculosis in China: A multicenter prospective cohort study - ScienceDirect
Frontiers | Application of Next Generation Sequencing for Diagnosis and Clinical Management of Drug-Resistant Tuberculosis: Updates on Recent Developments in the Field
WHO consolidated guidelines on drug-resistant tuberculosis treatment - NCBI Bookshelf
Therapy of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis. | Semantic Scholar
Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis | NEJM
WHO's Rapid Communication on Treatment of Multidrug- and Rifampicin-Resistant Tuberculosis | Stop TB Partnership
Factors associated with treatment outcome of MDR/RR-TB patients treated with shorter injectable based regimen in West Java Indonesia | PLOS ONE
Frontiers | Comparative effectiveness of individualized longer and standardized shorter regimens in the treatment of multidrug resistant tuberculosis in a high burden country
A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis | NEJM
Current WHO recommended design of multidrug-resistant TB regimens.... | Download Scientific Diagram
Fig. 4.1, Criteria to decide when the shorter MDR-TB regimen may be offered - WHO consolidated guidelines on drug-resistant tuberculosis treatment - NCBI Bookshelf
